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Edited by Beat ImhofAbstract Engagement of the immunoinhibitory receptor, pro-
grammed death-1 (PD-1) attenuates T-cell receptor (TCR)-
mediated activation of IL-2 production and T-cell proliferation.
Here, we demonstrate that PD-1 modulation of T-cell function
involves inhibition of TCR-mediated phosphorylation of ZAP70
and association with CD3f. In addition, PD-1 signaling atten-
uates PKCh activation loop phosphorylation in a cognate TCR
signal. PKCh has been shown to be required for T-cell IL-2
production. A phosphorylated PD-1 peptide, corresponding to
the C-terminal immunoreceptor tyrosine-switch motif (ITSM),
acts as a docking site in vitro for both SHP-2 and SHP-1, while
the phosphorylated peptide containing the N-terminal PD-1
immunoreceptor tyrosine based inhibitory motif (ITIM) associ-
ates only with SHP-2.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Immunoinhibition1. Introduction
The immunoreceptor, programmed death-1 (PD-1), is a
member of the immunoglobulin superfamily that is expressed
on a subset of thymocytes and on activated T- and B-cells, and
monocytes [1–3]. Mice deﬁcient in PD-1 display multiple au-
toimmune defects and a loss of peripheral tolerance [4–7]. The
ligands for PD-1, PD-L1 and PD-L2, are members of the B7
co-stimulatory molecules family [8] and are expressed on an-
tigen presenting cells, endothelial and epithelial cells, and on
activated lymphocytes [9–12]. Interaction of PD-1 with the li-
gands, PD-L1 and PD-L2, inhibits co-stimulation mediated
proliferation and cytokine secretion in T-cells [9,13,14]. The
inhibitory activity of PD-L1 and PD-L2 requires the expres-
sion of PD-1, as PD-1 deﬁcient T-cells show no inhibition of
anti-CD3 mediated proliferation by PD-1 ligands [9,13]. PD-1
acts as an immunoinhibitory molecule by downmodulating
both T-cell and B-cell responses [6,8,15].* Corresponding author.
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VDYGEL and a C-terminal immunoreceptor tyrosine-switch
motif (ITSM) TEYATIV [16], which in addition to PD-1 has
been described in CD2 subfamily members, as well as, cyto-
plasmic domains of the members of the SHP-2 substrate 1,
sialic acid-binding Ig-like lectin, carcinoembryonic Ag, and
leukocyte-inhibitory receptor families. The PD-1 ITSM asso-
ciates with SHP-2 and is required for PD-1 signaling in B cells
[8,17]. The N-terminal sequence is similar to the sequence I/L/
VXYXXL/V, which is deﬁned as the immunoreceptor tyrosine-
based inhibitory motif (ITIM) that recruits src homology-2
(SH2) domain containing phosphatases [18]. In B-cells, en-
gagement of PD-1 inhibits B-cell receptor (BCR) mediated
Ca2þ mobilization and phosphorylation of key signaling
molecules including Igb, Syk, PLCc2 and ERK1/2 [17]. The
inhibition of the BCR signaling cascade has been shown to be
directed by the recruitment of the SH2-domain containing
tyrosine phosphatase 2 (SHP-2) to the C-terminal phospho-
tyrosine of PD-1, but not the ITIM phospho-tyrosine [17].
We report here some molecular events in the PD-1 mediated
downmodulation of T-cell receptor (TCR) signaling. We
present evidence to show that in addition to the ITSM PD-1
peptide, the ITIM phospho-tyrosine peptide can also serve as a
docking site for SHP-2. We propose a membrane proximal
inhibitory mechanism for PD-1 in attenuation of ZAP70/CD3f
signalosome phosphorylation and consequently downmodu-
lation of the TCR signaling pathway.2. Materials and methods
2.1. Cells and stimulations
Mononuclear cells (Biological Specialties, Colmar, PA) were layered
on Ficoll–Histopaque (stem cell technologies) and the buﬀy coat was
collected following centrifugation. T-cell blasts were generated after 4
days in PHA (0.001%) alone and 3 days in PHA and 2 ng/ml IL-2.
Jurkat cells expressing hPD-1 with IRES-GFP were constructed using
an MSCV2.2-derived retroviral vector (provided by Dr. Kenneth
Murphy, Washington University, St. Louis, MO). Virus-containing
supernatants were produced in the 293-VSVg packaging line and used
to spin-infect cells followed by sorting for GFP expression. Cell surface
PD-1 expression was conﬁrmed by FACS analysis (data not shown)
and from several experiments determined to be comparable to PD-1
expression on PHA/IL-2 stimulated T-cell blasts. Recombinant hPD-
1.Fc and hPD-L1.Fc were generated as previously described [13]. Cells
were stimulated with anti-CD3e and IgG2a, or anti-CD3e andation of European Biochemical Societies.
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tosyl-activated beads (Dynal). Culture supernate was harvested for IL-
2 ELISA (R&D systems).
2.2. Biochemical and Western blot analysis
Whole cell lysates were prepared in 50 mM Tris–HCl, pH 7.4, 150
mM NaCl, 1 mM EDTA, 1% NP-40, or 50 mM Tris–HCl, pH 7.4, 1%
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 0.1% SDS, 1 mM
EDTA, 1 mM PMSF, with protease inhibitors (Boehringer–Mann-
heim) and phosphatase inhibitors (Calbiochem). Protein concentration
was determined (Pierce colorimetric assay) and extracts subjected to
SDS–PAGE and analyzed by Western blots; anti-CD3f (Immunotech),
anti-pTyr (Upstate), ERK1/2, and phospho-PKCh T538 (Cell Signaling
Technology), PKCh, pERK1/2, and SHP-2 (Santa Cruz), SHIP, SHP-
1 (Transduction Labs), IgG2a, anti-CD3e, anti-murine IgG, and anti-
CD28 (BD Biosciences), anti-PD-1 (Dr. T. Honjo, Kyoto University).
In some cases, densitometric scans of bands were obtained to deter-
mine the extent of PD-1 mediated signal inhibition.
2.3. Peptide precipitation
Biotinylated peptides for precipitation (Research Genetics) – ITIM
peptides: unphosphorylated (Y1); phosphorylated (pY1); scrambled
(pY1mix); tyrosine to phenylalanine mutant (Y1-F), and ITSM pep-
tides with cysteine to serine substitution (to eliminate potential peptide
dimerization) at position –5 aa relative to the TEYATI motif: un-
phosphorylated (Y2); phosphorylated (pY2); scrambled (pY2mix);
tyrosine to phenylalanine mutant (Y2-F). Jurkat cells (50 106)
treated for 10 minutes at 37 C with PMA (10 ng/ml) and ionomycin
(500 ng/ml) were lysed in modiﬁed RIPA buﬀer on ice. Lysates were
precleared with streptavidin sepharose, followed by precipitation using
peptides for 2 h and streptavidin sepharose for 1 h. Precipitations were
analyzed by SDS–PAGE and probed for SHIP, or SHP-1, or SHP-2.
For mass spectrometry analysis, SDS-PAGE bands were excised and
subjected to in gel tryptic digestion.3. Results and discussion
3.1. PD-1 engagement inhibits distinct TCR signal transduction
pathways
We investigated the consequence of PD-1 engagement on
TCR signaling pathways. TCR signaling induces distinct
downstream signal transduction pathways, including ERK
phosphorylation [19]. As in the case of B cell signaling, weFig. 1. PD-1 engagement inhibits PKCh and ERK activation in TCR signal
tivated beads co-ligated with anti-CD3e (1 lg/107 beads) and either isotype c
indicated times. Cell lysates were analyzed by Western blots – ﬁrst with a
(B) Human T-cell blasts were stimulated with tosyl-activated beads as in pane
3 days in culture. (C) Human T-cell blasts were stimulated with tosyl-activat
were analyzed by Western blots – probed ﬁrst with a phosphoT538 PKCh spobserve signiﬁcant PD-1 mediated inhibition of ERK activa-
tion (80% inhibition) in the presence of the TCR signal oc-
curring as early as 2 min following PD-1 engagement
(Fig. 1A). We veriﬁed PD-1 inhibition by monitoring IL-2
production in response to TCR activation using anti-CD3e
and either IgG2a or PD-L.Fc coated beads (Fig. 1B).
Thereafter, we investigated a distinct eﬀector arm of the
TCR signaling cascade involving the novel PKC subfamily
member, PKCh, which is required for T-cell IL-2 production
[20,21]. Phosphorylation at amino acid residue T538 in the
PKCh activation loop has been shown to support the cata-
lytically active conformation of the enzyme [22]. Using a PKCh
T538 phospho-speciﬁc antibody, we show that activation of T-
cells induces T538 phosphorylation within 2 min of stimulation
(Fig. 1C). However, when TCR is co-ligated with PD-L1.Fc,
PKCh T538 phosphorylation signal is signiﬁcantly inhibited, in
excess of 90% inhibition of the T-cell activation signal, as de-
tected by densitometric scanning of the results shown in
Fig. 1C, indicating that PD-1 engagement downmodulates
PKCh activation signal. These results suggest that distinct
arms of the TCR signal transduction pathway are inhibited by
PD-1 engagement, with modulation in the signaling cascade
upstream at a TCR proximal step.
3.2. PD-1 engagement inhibits the TCR phosphorylation signal
We next examined ZAP70 and CD3f tyrosine phosphory-
lation, a membrane proximal event in TCR signaling [19].
PD-1 mediated inhibition of IL-2 production in the PD-1
transduced Jurkat cell system was established using anti-CD3/
IgG or anti-CD3/PD-L1 co-immobilized beads both in the
absence and presence of soluble anti-CD28 (data not shown).
Jurkat cells were stimulated for 2 minutes and analyzed by
ZAP70 immunoprecipitation and Western blot using an anti-
phospho-tyrosine antibody (Fig. 2A). TCR crosslinking results
in ZAP70 tyrosine phosphorylation as shown in Fig. 2A left
panel using anti phospho-tyrosine blot and right panel show-
ing the loading control using anti ZAP70 blot. TCR induced
ZAP70 phospho-tyrosine signal is inhibited within 2 min of co-transduction. (A) Human T-cell blasts were stimulated with tosyl-ac-
ontrol or hPD-L1.Fc (4 lg/107 beads) and anti-CD28 (5 lg/ml), for the
phospho ERK1/2 speciﬁc antibody followed with ERK1/2 antibody.
l A at the indicated bead:cell ratios. IL-2 production was analyzed after
ed beads as in panels A and B for the indicated times, and cell lysates
eciﬁc antibody followed with anti-PKCh E7.
Fig. 2. PD-1 engagement inhibits ZAP70 and CD3f phosphorylation
and association. (A) Jurkat cells were stimulated with tosyl-activated
beads co-ligated with anti-CD3 (1 lg/107 beads) and either IgG
isotype control or hPD-L1.Fc (4 lg/107 beads) for 2 min, and cells
were lysed in RIPA lysis buﬀer. ZAP70 CD3f was immuno-
precipitated from equal amounts of protein and immune complexes
were analyzed by Western blot for anti phosphor-tyrosine and
anti-ZAP70. (B) Jurkat cells were stimulated, then lysed in NP-40
lysis buﬀer to maintain protein interactions, followed by ZAP70 or
CD3f immunoprecipitation from equal amounts of protein. Immu-
nocomplexes were analyzed for anti phospho-tyrosine and anti-
ZAP70.
Fig. 3. Both SHP-1 and SHP-2 associate with PD-1 in a phosphorylation de
ITIM (Y1) and ITSM (Y2) sequences used for precipitating proteins from Ju
in panel B were analyzed for SHP-2 by Western blot. (C) Precipitated proteins
blot. (D) Jurkat cells were either pervanadate treated or untreated and cells
itations. The immune complexes were analyzed by Western blot for both SH
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bition observed in these experiments as detected by densito-
metric scanning is 85%.
Activated ZAP70 associates with tyrosine phosphorylated
CD3f to potentiate the downstream TCR signal. [19,23]. Upon
TCR crosslinking phosphorylated CD3f is detected as a 23 kD
phospho-tyrosine protein in ZAP70 immuneprecipitated
complex from Jurkat cell lysates, as shown in Fig. 2B left
panels by the anti ZAP70 and antiphospho-tyrosine blots. In
this experiment, we demonstrate that PD-1 engagement at-
tenuates the TCR induced association of the 23 kD phospho-
tyrosine protein with ZAP70 by about 50% as detected by
densitometric scanning of the two lanes in Fig. 2B lower left
panel. We further analyzed immunoprecipitated CD3f from
cell lysates by anti phospho-tyrosine blots to show that TCR
induced CD3f phospho-tyrosine signal is inhibited 70%,
upon TCR/PD-1 co-ligation (Fig. 2B right panel). This result
shown is representative of four independent experiments which
were repeated using equivalent amount of protein lysate in
immuneprecipitations, as the anti CD3f antibody did not give
adequate Western blot signal perhaps due to low aﬃnity of the
antibody in both the immunoprecipitation and blotting (actin
Western blot controls not shown). Collectively, these ﬁndings
indicate that the PD-1 signal attenuates TCR induced CD3f
chain and ZAP70 tyrosine phosphorylation.pendent manner. (A) Biotinylated peptides corresponding to the PD-1
rkat cell lysates. (B) Precipitated proteins from activated Jurkat cells as
from activated Jurkat cell lysates were analyzed for SHP-1 by Western
were lysed in NP-40 lysis buﬀer for SHP-2 and PD-1 immunoprecip-
P-2 and PD-1.
Fig. 4. PD-1 peptide precipitated protein identiﬁcation and model for
TCR downmodulation by PD-1. (A) Precipitated proteins from Jurkat
cell lysates using the phospho-ITIM and phospho-ITSM peptides de-
scribed in Fig. 3 were separated by SDS–PAGE and silver stained,
followed by MS identiﬁcation of in-gel tryptic digested peptides from
sliced gel bands indicated by brackets (denoting the gel bands corre-
sponding to SHP-1 and SHP-2 peptides) and asterix (denoting the gel
band corresponding to Lck and Csk peptides). The table lists the
peptide numbers identiﬁed for each protein in the PD-1 peptide pre-
cipitation indicated. (B) In the resting or unstimulated TCR signalo-
some, Lck is phosphorylated on its negative regulatory tyrosine residue
(indicated by the red circle) by PAG/Cbp associated Csk kinase ac-
tivity. Co-ligation of the TCR with PD-1 results in SHP-2 phosphor-
ylation (and perhaps PD-1) presumably by Lck or Csk, as indicated by
dashed lines. PD-1 suppresses TCR signaling likely via a recruited SHP
phosphatase activity corresponding with decreased phosphorylation of
the CD3f ITAM sites, attenuated ZAP70 activation, and inhibition of
downstream signal transduction. The phosphorylation sites in the cy-
toplasmic domains of the indicated receptors and signaling molecules
are denoted in black circles or rectangles.
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SHP-1 and SHP-2, in T-cells
In B cells, the PD-1 C-terminal ITSM has been shown to
associate with SHP-2, and not SHP-1, and the N-terminal
ITIM is not required [17]. We have shown previously SHP-2
phosphorylation upon PD-1 engagement in T-cells [9].
Therefore, we queried the PD-1:SHP-2 interaction of T-cells
and asked if one or both of the cytoplasmic tyrosine motifs
facilitate this interaction. We utilized a precipitation approach
of activated Jurkat cell lysates with peptides corresponding to
either the PD-1 ITIM or the PD-1 ITSM (Fig. 3A). Interest-
ingly, SHP-2 associates with both the phospho-ITIM pY1 and
phospho-ITSM pY2 peptides, however, a quantitatively higher
amount of SHP-2 associates with phospho-ITSM pY2 than
with phospho-ITIM pY1 (Fig. 3B, lanes 1 and 4). No SHIP
binding to PD-1 peptides was detected in these studies (data
not shown). SHP-1 binding is detected only in the phospho-
ITSM pY2 peptide precipitated complex (Fig. 3C, lane 5). This
suggests a phosphorylation dependent docking of SHP-1 spe-
ciﬁcally to the PD-1 phospho-ITSM pY2 and not the phospho-
ITIM pY1 sequence.
To conﬁrm a phosphorylation dependent PD-1:SHP-2 en-
dogenous association, PD-1 was immunoprecipitated from
pervanadate treated or untreated Jurkat cells and analyzed
for co-precipitation (Fig. 3D). Treatment with pervanadate,
an inhibitor of tyrosine phosphatases, will favor the detection
of a tyrosine phosphorylation dependent interaction. SHP-2
and PD-1 co-precipitated from pervanadate treated cells and
not untreated cells, consistent with a phosphorylation de-
pendent association. We did not observe any endogenous
PD-1:SHP-1 association (data not shown), perhaps due to
diﬀerences in expression levels or a competing PD-1:SHP-2
association.
SHP-1 and SHP-2 association with PD-1 phospho-peptides
was further conﬁrmed by mass spectrometric identiﬁcation of
phospho-peptide precipitated protein bands. Fig. 4A shows the
silver stained gel, indicating the major protein bands that re-
sulted in the identiﬁed peptides as shown in the table. No
endogenous PD-1:SHP-1 association was detected from per-
vanadate treated cells, and it is further likely that the homol-
ogy between SHP-1 and SHP-2 led to the in vitro association
observed with the phospho-ITSM pY2 peptide (Fig. 3). In
excess of ﬁfty peptides, each from SHP-1 and SHP-2 was de-
tected in the peptide precipitated proteins identiﬁed by MS,
again with SHP-1 being ITSM pY2 speciﬁc (Fig. 4A). Four C-
terminal Src kinase (Csk) peptides were identiﬁed as ITSM
pY2 speciﬁc and one Lck peptide as ITIM pY1 speciﬁc. Upon
co-ligation of PD-1 and the TCR, the rapid phosphorylation
of SH-2 domain phosphatase SHP-2 [9], and perhaps PD-1,
may be mediated by a Src family kinase, thereby activating the
phosphatase [24] and downmodulating the TCR signal
(Fig. 4B). Consistent with this model Okazaki et al. [17] report
that Src family kinase, Lyn, phosphorylates PD-1 in B-cells. In
the TCR resting state, the negative regulatory tyrosine on Lck
is phosphorylated by Csk [19,25]. Downmodulation of CD3f
by PD-1 likely involves both tyrosine phosphorylation of SHP-
2 and PD-1 and perhaps negative regulation of tyrosine kinase
activities via Csk and Lck.
Crystal structure and mutation analysis of SHP-2 support a
phosphatase active conformation when the SH-2 domains bind
a biphosphorylated ligand [18,26,27]. We show that SHP-2
associates with both the ITIM pY1 and ITSM pY2 (Fig. 3B),suggesting that the in vivo association in T cells may involve
binding to a biphosphorylated PD-1 cytoplasmic region. Lu et
al. [24] report that phosphorylation of the two C-terminal ty-
rosine residues of SHP-2 signiﬁcantly stimulates catalytic ac-
tivity, again likely due to association of the biphosphorylated
C-terminal tail with the SH2-domains. PD-1 engagement
mediated phosphorylation of SHP-2 [9] may positively regulate
phosphatase activity by a similar structural mechanism. The
immunoinhibitory receptor BTLA (B and T lymphocyte at-
tenuator), like CTLA-4, has homology to PD-1 [28]. SHP-2
can associate with the cytoplasmic tail of CTLA-4 and this
association also requires phosphorylation of the tail motif by
Lck [29]. Similarly, BTLA has been shown to recruit SHP-1
and SHP-2 upon crosslinking [28]. It is likely that BTLA en-
gagement also results in SHP-1/2 being phosphorylated, as has
been shown for SHP-2 by PD-1 ligation [9].
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on many tissues types, Zang et al. [30] suggest that BTLA may
modulate T-cell responses to tissue speciﬁc antigens. CTLA-4
has a role in early T-cell activation, anergy, and self reactive
immunity [8,31]. Recently, it has been shown that CTLA-4
deﬁcient T-cells bypass the STAT6 requirement in Th2 diﬀer-
entiation, suggesting that CTLA-4 signaling potentiates the
Th2 lineage cytokine signals [32]. PD-1 has a role in dysregu-
lation of self reactive immune cells [4] and positive selection of
thymocytes, aﬀecting the mature T-cell repertoire [5]. BTLA,
CTLA-4, and PD-1 are likely contributing to distinct immu-
nomodulatory roles during development, antigen challenge,
and disease. For each of these molecules, the receptor proximal
recruitment of tyrosine phosphatases appears to be a key sig-
naling mechanism. We show here that PD-1 inhibition of T-
cells also involves SHP1/2 association.More signiﬁcantly, PD-1
mediated inhibitory signal blocks the ZAP70/CD3f signalo-
some resulting in attenuated PKCh activation and signaling to
IL-2 production.
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